• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >RANDOMIZED TRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATION.
【24h】

RANDOMIZED TRIAL EVALUATING SHORT-TERM EFFECTS OF INTRAVITREAL RANIBIZUMAB OR TRIAMCINOLONE ACETONIDE ON MACULAR EDEMA AFTER FOCAL/GRID LASER FOR DIABETIC MACULAR EDEMA IN EYES ALSO RECEIVING PANRETINAL PHOTOCOAGULATION.

机译：糖尿病性黄斑水肿的局灶/ GR激激光治疗后，随机给予雷尼替莫拉或曲安奈德丙酮对黄斑乙二胺的短期疗效评估，同时也接受全角膜光凝。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE:: To evaluate 14-week effects of intravitreal ranibizumab or triamcinolone in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation. METHODS:: Three hundred and forty-five eyes with a visual acuity of 20/320 or better, center-involved diabetic macular edema receiving focal/grid laser, and diabetic retinopathy receiving prompt panretinal photocoagulation were randomly assigned to sham (n = 123), 0.5-mg ranibizumab (n = 113) at baseline and 4 weeks, and 4-mg triamcinolone at baseline and sham at 4 weeks (n = 109). Treatment was at investigator discretion from 14 weeks to 56 weeks. RESULTS:: Mean changes (+/-SD) in visual acuity letter score from baseline were significantly better in the ranibizumab (+1 +/- 11; P < 0.001) and triamcinolone (+2 +/- 11; P < 0.001) groups compared with those in the sham group (-4 +/- 14) at the 14-week visit, mirroring retinal thickening results. These differences were not maintained when study participants were followed for 56 weeks for safety outcomes. One eye (0.9%; 95% confidence interval, 0.02%-4.7%) developed endophthalmitis after receiving ranibizumab. Cerebrovascular/cardiovascular events occurred in 4%, 7%, and 3% of the sham, ranibizumab, and triamcinolone groups, respectively. CONCLUSION:: The addition of 1 intravitreal triamcinolone injection or 2 intravitreal ranibizumab injections in eyes receiving focal/grid laser for diabetic macular edema and panretinal photocoagulation is associated with better visual acuity and decreased macular edema by 14 weeks. Whether continued long-term intravitreal treatment is beneficial cannot be determined from this study.
机译：目的：：评估玻璃体腔内兰尼单抗或曲安西龙在接受聚焦/栅格激光治疗糖尿病性黄斑水肿和视网膜光凝的眼睛中的14周效果。方法：将345只视力为20/320或更高的眼，中心聚焦的糖尿病性黄斑水肿接受聚焦/网格激光治疗，糖尿病性视网膜病变接受及时的全视网膜光凝治疗（n = 123）随机分配。 ，基线和4周时0.5 mg雷珠单抗（n = 113），基线时4 mg曲安西龙和假手术4周（n = 109）。治疗由研究人员决定，从14周到56周不等。结果：雷尼单抗（+1 +/- 11; P <0.001）和曲安西龙（+2 +/- 11; P <0.001）与基线相比，视力字母得分的平均变化（+/- SD）明显更好。与第14周的假手术组（-4 +/- 14）进行比较，反映出视网膜增厚的结果。当安全性结果被随访56周时，这些差异没有得到维持。接受兰尼单抗治疗后，一只眼睛（0.9％; 95％置信区间，0.02％-4.7％）发展为眼内炎。假，兰尼单抗和曲安西龙组分别有4％，7％和3％发生脑血管/心血管事件。结论：在接受聚焦/栅格激光治疗的糖尿病性黄斑水肿和全视网膜光凝的眼睛中，添加1次玻璃体内曲安奈德注射液或2次玻璃体内兰尼单抗注射液可改善视力，并减少黄斑水肿14周。从这项研究无法确定长期持续的玻璃体内治疗是否有益。

著录项

  • 来源
    《Retina》 |2011年第6期|共19页
  • 作者

    Stockdale CR;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 眼科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号